Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "medicine"

2183 News Found

Amgen opens new technology and innovation site in Hyderabad
Digitisation | February 25, 2025

Amgen opens new technology and innovation site in Hyderabad

Amgen India investment totals $200 million through 2025


Teva and Sanofi present new outcome from Phase 2b study of duvakitug
News | February 25, 2025

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025


European Commission approves Biocon Biologics' Ustekinumab Biosimilar
News | February 21, 2025

European Commission approves Biocon Biologics' Ustekinumab Biosimilar

YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease


Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer
Drug Approval | February 20, 2025

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved


Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
News | February 17, 2025

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified


AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
People | February 15, 2025

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

Richard A. Gonzalez to retire from the board of directors effective July 1, 2025


Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients
News | February 15, 2025

Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients

Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone